APVO — Aptevo Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.74m
- -$4.97m
- 14
- 40
- 16
- 12
Annual cashflow statement for Aptevo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.8 | -28.5 | 8.03 | -17.4 | -24.1 |
| Depreciation | |||||
| Non-Cash Items | -10.6 | 8.29 | -32.1 | 2.2 | 1.07 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.41 | -2.65 | 2.14 | 2.91 | -1.08 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -29.3 | -21.7 | -21 | -11.7 | -23.8 |
| Capital Expenditures | -0.088 | -0.713 | -0.029 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 28.1 | 0 | — | — | 0 |
| Sale of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 28 | -0.713 | -0.029 | 0 | 0 |
| Financing Cash Flow Items | -0.011 | 25.3 | 2.72 | -0.01 | -0.004 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 23.9 | 26.2 | -2.62 | 6 | 15.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 22.6 | 3.77 | -23.7 | -5.73 | -8.19 |